Combined Strategy Using Myoblasts and Hepatocyte Growth Factor in Dilated Cardiomyopathic Hamsters

摘要: Background There are few reports on treating dilated cardiomyopathy (DCM) with myoblast transplantation, and these show limited efficacy. Hepatocyte growth factor has cardioprotective effects failed myocardium. Here, we combined two treatments analyzed cardiac function in DCM hamsters. Methods Twenty-seven-week-old BIO TO-2 hamsters, which moderate remodeling, were divided into four treatment groups: transplantation (T group, n=24), human hepatocyte gene transfection (H n=29), (T+H n=21), medium alone (C n=26). Results Significantly better fractional shortening was observed the T+H group compared others (14.9% ± 1.0%, 11.7% 1.5%, 11.3% 1.3%, 8.6% 1.1 %, T+H, H, T, C groups, respectively). Immunohistochemical analysis showed alpha- beta-sarcoglycan expression hearts of H groups but not other groups. less myocardial fibrosis than two, neovascularization significantly greater (266 24, 209 27, 199 36, 96 17 vessels/mm 2 , Survival prolonged Conclusions preserved probably through different mechanisms, performance either alone. The therapy is a promising strategy for DCM.